Key Highlights

  • Shares of Lyell Immunopharma (NASDAQ:LYEL) advanced 42.95% across the week, reaching USD 15.73 after results and a USD 80.0 million Placement arrived on November 4, 2026.
  • Capricor Therapeutics (NASDAQ:CAPR) climbed 31.93% in the week to USD 8.23, with no weekly trigger confirmed before the November 22, 2026 FDA decision date for deramiocel.
  • Silence Therapeutics (NASDAQ:SLN) moved just 0.23% over the week to USD 19.76, but its one-month advance of 95.21% places it third among 1,259 small caps, tied to divesiran Phase 2 results.
  • Each of the three is clinical stage with little or no revenue, so each price turns on trial results, a regulatory calendar or fresh financing, and each carries the thin trading and wide spreads common to small caps valued from USD 300 million to USD 2 billion.

Silence Therapeutics (NASDAQ:SLN): A Small Weekly Move After a Large Monthly Run

Silence Therapeutics (NASDAQ:SLN) ended the session at USD 19.76 on November 5, 2026. Its weekly change was a slight 0.23% gain, while the monthly figure reads 95.21%, which works out to a price near USD 10.12 a month earlier by simple arithmetic. Nothing in the pages reviewed ties the recent weeks to a specific news item. The earlier turning point was the SANRECO Phase 2 study of divesiran in polycythemia vera, reported on August 10, 2026, where the drug hit its main goal with an 88% clinical response against 19% for the placebo arm, and shares climbed 35.3% that day. Dosing every six weeks yielded a 93.8% response rate, against 81.3% for dosing every twelve weeks, and no fresh safety concerns surfaced in the 48 patients who depended on phlebotomy. Strong randomized data in a rare blood disease can raise hopes for approval and for a partner, and buyers chasing momentum may have pushed the price higher too, though that remains general context. Plans call for a Phase 3 study of quarterly dosing in the first half of 2027, alongside possible IND submissions for SLN365 and SLN098 during 2027, and Cantor Fitzgerald set an Overweight rating on June 24, 2026. The stock has gained 219.14% so far this year, 65.18% across three months and 188.39% across six. Cash of USD 72.1 million at June 30, 2026 compares with a six month net loss of USD 27.2 million, which makes a share sale before a 2027 Phase 3 start a real possibility. Because it is a small cap, a handful of trades can shift the quote, and the bid and ask can sit far apart.

Lyell Immunopharma (NASDAQ:LYEL): Earnings and a Placement Behind a 42.95% Weekly Rise

Third quarter results arrived on November 4, 2026, and so did an USD 80.0 million private placement. Lyell Immunopharma (NASDAQ:LYEL) changed hands at USD 15.73 on the latest read, rising 42.95% across the week and 72.23% across the month, which ranks it among the stronger small caps on both time frames. Its net loss grew to USD 45.5 million from USD 38.8 million. Cash was USD 194.0 million at September 30, 2026, and Leadership indicated that cash together with the placement proceeds covers operations into 2028. Management's release emphasizes pivotal program progress as the driving force, yet no single headline can be linked to the price move. Data from the PiNACLE study of ronde-cel in third-line and later large B-cell lymphoma covered 44 patients who could be assessed for efficacy, showing a 91% overall response rate and a 77% complete response rate. Pivotal results are slated for mid-2027 and a Biologics license application in the second half of 2027. Grade 3 or higher ICANS affected 9% of patients, and no grade 3 or higher cytokine release syndrome appeared. Attention will also turn to ASH presentations between December 12 and 15, 2026. A Market Value of about USD 382.28 million sits roughly two times the cash balance, a comparison built from two published numbers. Eight analysts, per published coverage, sit at a Buy consensus with a USD 37.88 average target, which is reported information and not a recommendation. Over six months the shares are down 21.10%, and year to date down 49.79%, so the advance unfolds inside a steep decline and a 52-week range of USD 7.20 to USD 45.00. A recent reading of 83,379 shares points to light trade, wide spreads are possible, and the placement adds dilution exposure.

Capricor Therapeutics (NASDAQ:CAPR): A Regulatory Date Keeps a 31.93% Weekly Rally Volatile

Little new happened for this name in the week under review, at least in the pages examined. Capricor Therapeutics (NASDAQ:CAPR) is quoted at USD 8.23, a gain of 31.93% on the week that was partly reversed by a 7.71% slide in the latest session. Stocks facing a yes or no regulatory ruling often swing in both directions as the deadline approaches, because traders keep adding or trimming positions. The FDA pushed the decision on the deramiocel biologics license application from August 22, 2026 to November 22, 2026, after classifying a company amendment as major. That filing includes 24 month open label extension results and a narrower indication for the upper limb. HOPE-3, a placebo controlled Phase 3 study with 106 patients, released 12 month findings in July 2026, and an extension update arrived on October 5, 2026. Revenue is zero and the net loss reached USD 129.4 million, so the Equity case depends on the regulator's verdict. Market value stood at USD 384.3 million when shares were USD 5.88 on July 12, 2026, and a share count of roughly 65.4 million implies about USD 538 million at USD 8.23, a figure produced by calculation. On August 21, 2026, a holder named Kaos Capital requested a board session within 15 Business days. The published consensus target of USD 27.00 sits 228% above the current quote by calculation, but it is not a forecast. A rejection or postponement could undo the advance, a fresh stock sale could dilute holders, and thin trading means a few orders can move the price.

Where Things Stand

Third quarter results and an USD 80.0 million placement drove Lyell Immunopharma (NASDAQ:LYEL) to a 42.95% weekly gain. Capricor (NASDAQ:CAPR) followed at 31.93%, with its path set by a regulatory date. Silence Therapeutics (NASDAQ:SLN) added only 0.23% on the week after a far larger monthly run. All three are clinical stage biotechs, so prices hinge on trial data, regulatory dates and financing. The grouping reflects small caps valued from USD 300 million to USD 2 billion, drawn from a published screener snapshot dated November 5, 2026, and rallies of this size can reverse because trading is thin, spreads are wide and binary events cut both ways.